SlideShare a Scribd company logo
1 of 56
“POLYMERIC NANOPARTICLES
FOR TARGETED DELIVERY”
By:
Dr. A. R. Kulkarni,
Assoc. Professor,
Dept of Pharmacology,
K.L.E.S’s College of
Pharmacy,
Belgaum-10
“POLYMERIC NANOPARTICLES
FOR TARGETED DELIVERY”
By:
Dr. A. R. Kulkarni,
Assoc. Professor,
Dept of Pharmacology,
K.L.E.S’s College of Pharmacy,
Belgaum-10
Contents
• Introduction to targeted drug delivery system
• Bioavailability, efficiency, efficacy
• Volume of distribution v/s drug toxicity
• Drug receptor concept
• Nature of receptors
• Site specificity
• Antigen- Antibody mechanism
• Advantages of targeting
• Mechanism of targeting
• Classifications of targeting
• Importance of transport system
• Polymeric nanoparticles
Introduction to Targeted Drug Delivery System
Definition:
‘Targeted drug delivery’
Carriers, They are drug vectors,
Bioavailability
F = Bioavailable dose
Administered dose
Bioavailability – Absolute v/s Relative
Drug efficiency:
Drug efficacy:
Apparent volume of distribution (V) :
V = dose administered i.v.
plasma concentration
Drug toxicity:
Ideal systemic delivery vector
• Non-toxic vehicle
• Non-immunogenic
• Condensation of DNA
• Intracellular delivery
• Targeting ligand
• Stabilization of particles
Carrier systems used for targeted drug delivery:
1. Colloidal carriers
a) Vesicular systems
Liposomes, niosomes, pharmacospheres, virosomes.
b) Microparticulate system
Microparticles, nanoparticles, magnetic microspheres
2. Cellular carriers
Released erythrocytes, serum albumin, antibodies, platelets
3. Supramolecular delivery systems
Micelles, reverse micelles, mixed micelles, polymeric micelles
4. Polymer based systems
Signal sensitive, mucoadhesive, biodegradable, bioerodable
5. Macromolecular carriers
a) Proteins
b) Glycosylated water soluble polymers
c) Toxins, immunotoxin and rCD4 toxin conjugates
d) Lectins and polysaccharides
Volume of Distribution v/s Drug Toxicity
Drug receptor concept
• Binding of drugs to receptors necessarily obeys
the Law of Mass Action
• At equilibrium, receptor occupancy is related to
drug concentration by the Hill- Langmuir
equation
• The higher the affinity of the drug for the
receptor, the lower the concentration at which it
produces a given level of occupancy
• The same principles apply when two or more
drugs compete for the same receptors, each
has the effect of reducing the apparent affinity
of the other
Site specificity
• Drug is a chemical that affects physiological
function in a specific way
• With few exceptions drugs act on target
proteins namely- enzymes, carriers, ion
channels, receptors
• Specificity is reciprocal: individual classes of
drug bind only to certain targets, & individual
targets recognize only certain classes of drug
• No drugs are completely specific in their action
• In many cases, increasing the dose of a drug
will cause it to affect targets other than the
principal one, and this can lead to side-effects
Antigen antibody mechanism
Mechanism of targeting
• Passive targeting
• Active targeting
• Inverse targeting
• Physical targeting
• Dual targeting
Active targeting further classified into…
1. First order targeting
Refers to restricted distribution of the drug carrier
system to the cappilary bed of a predetermined
target site, organ or tissue
Ex. Compartmental targeting in lymphatics, peritoneal cavity, plural cavity,
lungs, joints
2. Second order targeting
Refers to selective delivery of drugs to a specific cell
type such as tumor cells & not the normal cells
Ex. The selective drug delivery to the Kupffer cells in the liver exemplifies
this approach
3. Third order targeting
Refers to drug delivery specifically to the internal
(intracellular) site of target cells
Physical targeting
• This is selective drug delivery programmed &
monitored at the external level (ex-vivo) with the
help of physical means
• In this mode of targeting , some characteristics
of the environment are used to direct the carrier
to a particular location or to cause selective
release of its contents
Dual targeting
Factors affecting the biodistribution
of nanoparticles
• Surface hydrophobicity:
The higher the nanoparticle hydrophobicity, the faster
the nanoparticles are removed from the circulation
and taken up by the cells of the MPS
• Surface charge:
Negative surface charge increases the clearance of
nanoparticulates, relative to neutral or positively
charged surfaces
• Surface size:
Nanoparticles more than 5000 nm are normally
entrapped in the capillary network of the lungs
Nanoparticles less than 100 nm may be able to leave
the circulation through gaps or fenestrations in the
endothelial cells lining the blood vessels
Polymeric nanoparticles
• As the name suggests polymeric nanoparticles
are nanoparticles which are prepared from
polymers
• In recent years these have attracted
considerable attention as potential drug
delivery devices in view of their applications in
- drug targeting to particular organ/tissue
- as carriers of DNA in gene therapy
- ability to deliver proteins, peptides and genes
through per oral route of administration
• In spite of various synthetic & semisynthetic
polymers, natural polymers still enjoy their
popularity
- gums (ex. Acacia, guar, etc.)
- chitosan
- gelatin
- sodium alginate
- albumin
• Polymer used must be chemically inert, non-
toxic and free of leachable impurities
• It must have appropriate physical structure,
with minimal undesired aging & be readily
processable
• Polymers dsigned for medical applications are
designed to degrade within the body
- polyactides (PLA)
- polyglycolides (PGA)
- poly (lactide-co-glycolides) (PLGA)
- polyanhydrides
- polyorthoesters
- polycyanoacrylats
- polycaprolactone
• Advantage of degradable polymers- they are
broken down into biologically acceptable
molecules that are metabolized and removed
from the body via normal metabolic pathways
Fact:
• Abraxane is first polymeric nanoparticle based
product from American Pharmaceutical
Partners, Inc., and American Bioscience, Inc.
(ABI)
• It was approved in the year 2005 and is
consisting of albumin bound paclitaxel
nanoparticles
Emulsion polymerization
• In this method, the monomer is dispersed in
aqueous solution as a uniform emulsion and
stabilized by the surfactants.
• Dispersion of the surfactant persists until the
critical micellar concentration (CMC) is
realized.
• The anionic polymerization of
polyalklycyanoacrylate monomers into
polymeric NPs follows the emulsion
polymerization technique.
PRODUCTION OF NANOPARTICLES BY
DIFFERENT TECHNIQUES
• Dispersion polymerization
NPs of polyacrylamide (PAM) by the dispersion
polymerization of acrylamide monomer at 40°C.
They used the partial isopropyl ester derivative of
poly(vinyl methyl ether-alt-maleicanhydride)
(PVME-alt-MA), called PVME-co-MA-co-iPrMA, as
the stabilizer, and ammonium persulfate (APS) as
the initiator.
• Solvent diffusion and evaporation
Water insoluble polymers can be used for
production of NPs.
• The in vivo biodistribution of NPs is greatly
influenced by their interactions with the plasma
proteins.
• Opsonization by plasma proteins renders the NPs
more vulnerable to mononuclear phagocytotic
attack, mainly by the Kupffer cells of the liver.
• In fact, the main disadvantage of drug targeting to
the CNS is the rapid uptake of NPs by the
macrophages of the RES, thus hindering NP
applications in controlled drug delivery and drug
targeting, to tissues other than those of the RES.
SURFACE MODIFICATION OF NANOPARTICLES
• Therapeutic drug levels of the targeted (e.g., brain)
drug-loaded NPs are therefore difficult to reach.
Tween-80
• It was demonstrated that substances which could not
otherwise cross the BBB, can induce permeability
when the substance is bound onto the surfaces of
poly (cyanoacrylate) nanoparticles, and coated with
surfactants, such as Tween-80.
• It seemed that brain targeting of nanoparticles was
concerned with the interaction between Tween-80
coating and brain micro-vessel endothelial cells.
• Kreuter et al have extensively discussed the
nanoparticle mediated drug transport to the brain
overcoated with polysorbates and other surfactants.
Polyethylene glycol
• The presence of the hydrophilic coating on the
surface of the nanoparticles is thought to sterically
stabilize them against opsonization and phagocytocis.
• Among the hydrophilic polymers, polyethylene glycol
(PEG) has been found to be a particularly effective
steric stabilizer, probably due to its high
hydrophilicity, chain flexibility, electrical neutrality and
absence of functional groups, which prevent
interactions with the biological components in vivo.
• The NP surface coating with hydrophilic polymers such
as PEG has been shown to confer long circulation
properties to poly(lactide) (PLA), poly(lactide-co-
glycolide) (PLGA), poly (caprolactone) (PCL) and poly
(phosphazene) and poly(cyanoacrylate) nanoparticles.
Poloxamer/Poloxamine
• The drug-loaded NPs were surface-modified with block
copolymers of the poloxamer 407 or poloxamine 908
series, and administered intravenously to rats under
study.
• It was demonstrated that the blood circulation half-life
was increased by its encapsulation in the surface-
modified NPs (25-30 min), whereas uncoated NPs
rapidly cleared from the blood (only 8 % remaining after
5 min).
• Additionally, the amount of NPs in the liver was found to
significantly decrease after NPs encapsulation within the
modified NPs.
• Similar correlations were made regarding decreases in
splenic uptake of coated nanoparticles. Thus, PLGA
nanoparticles successfully escaped capture by the RES.
PCS of Empty NP
Effects of the CS-γ-PGA NPs on the TEER values of
Caco-2 cells.
+
Chitosan
+
+
+
+
+
+
+
+
+
γPGA
Nanoparticles with a positive surface charge
were able to reduce the values of TEER.
Time (hr)
TEER
of
Initial
Value
(%)
1 2 3
0 4
20
40
60
80
100
120
Control Group 0.01% -PGA:0.05% CS
0.10% -PGA:0.20% CS
0.20% -PGA:0.01% CS
(n = 3)
Removal of
Nanoparticles
Time (hr)
TEER
of
Initial
Value
(%) 0 4 8 12 16 20 24
20
40
60
80
100
120
Removal of
Nanoparticles
Control Group 0.01% -PGA:0.05% CS
0.10% -PGA:0.20% CS
0.20% -PGA:0.01% CS
(n = 3)
Figure 2. Effects of the prepared CS–-
PGA nanoparticles on the TEER values of
Caco-2 cell monolayers.
Nanopharmacuticals for the
treatment of cancers
we have developed paclitaxel-loaded formulations using the
nanoparticles for the treatment of cancers.
Paclitaxel is one of the most active anticancer drugs
introduced in cancer chemotherapy
Even though paclitaxel is prescribed mainly to treat breast
and ovarian cancers, it is known that various cancer cells
including hepatoma cells can be killed effectively by this
drug
PACLITAXEL- LOADED NANOPARTICLES
Nanoparticles may be delivered to specific sites
by size-dependant passive targeting or by active targeting
Hepatoma cells are known to recognize galactose-
and N-acetylgalactosamine-terminated glycoproteins
via the asialoglycoprotein (ASGP) receptors located on
their surfaces
Galactosylated Nanoparticle
Galactosamine
Synthesis of γ-PGA-PLA block copolymers
PGA produced by Bacillus licheniformis (ATCC 9945,
Bioresources Collection and Research Center, Hsinchu,
Taiwan) and purified
Block copolymers composed of PGA and PLA were
synthesized using CDI to activate the terminal hydroxyl
group of PLA
Galactosamine was conjugated to the paclitaxel-loaded
nanoparticles via an amide linkage by EDC
OH
C
O
CH
CH3 n
PLA
O
CH2 O O
C
O
CH
CH3 n
O
CH2 O C N
O N
-PGA
m
NH
CH
CH2
CH2
C
C
O OH
O
NH2
OH
Amphiphilic
Block Copolymer
N
N C N
O N
Galactosylated Nanoparticle
Galactosamine
CDI
Activated PLA
AFM Photographs
Particle size, zeta potential, and drug loading content (LC)
and loading efficiency (LE) of the paclitaxel-loaded
nanoparticles without (NPs) or with (Gal-NPs) galactosamine
Samples (n =
4)
Particle Size (nm) Zeta Potential
(mV)
LC
(%)
LE
(%)
NPs 128.8 ± 3.4 -19.6 ± 1.8 5.1 ± 0.2 53..7 ± 1.6
Gal-NPs 127.5 ± 2.5 -10.6 ± 2.0 4.8 ± 0.2 50..2 ± 2.1
-20 0 20 40 60 80 100 120 140 160
10
20
30
40
50
60
70
80
90
100
Accumulative
Release
of
Paclitaxel
(%)
Time (h)
NPs
Gal-NPs
(n = 4)
-1 0 1 2 3 4 5 6 7 8 9
60
65
70
75
80
85
90
95
100
105
Phyxol
NPs
Gal-NPs
(n = 4)
Incubation for 1 day
Cells were fixed with 3.7% formaldehyde in PBS cells
were stained with Oregon Green and propidium iodide
(PI, Sigma) that specifically bind to F-actin and the
nucleus, respectively.
Additionally, microtubule networks were revealed using a
monoclonal anti-bovine -tubulin, with an anti-mouse
IgG-Alexa Fluor 633 (Molecular Probes).
Immunofluorescence analysis
F-actin Nucleus Microtubule Merge
N
N
n
Control
Phyxol

n
Immunofluorescence analysis
Liver
Spleen
Tumor
NPs Gal-NPs
NPs or the Gal-NPs loaded with rhodamine 123
n
NPs
Gal-NPs
n
n
F-actin Nucleus Microtubule Merge
1 2 3 4 5 6
0
10
20
30
40
50
60
70
80
90
100
110
120
130
Tumor
Kidney
Lung
Liver
Spleen
Brain
Blood
Intensity
(counts/mg
tissue)
1 h after injection
8 h after injection
24 h after injection
(n=4)
1 2 3 4 5
0
10
20
30
40
50
60
70
80
90
100
110
120
Tumor
Kidney
Lung
Liver
Spleen
Brain
Blood
Intensity
(counts/mg
tissue)
1 hafterinjection
8 hafterinjection
24 hafterinjection
(n=4)
0 2 4 6 8 10 12 14 16 18 20 22
0.70
0.75
0.80
0.85
0.90
0.95
1.00
1.05
Changes
in
the
Body
Weight
(
%)
PBS
Phyxol
NPs
Gal-NPs
CONCLUSIONS
Drug-loaded nanoparticles with galactosamine
conjugated prepared in the study can effectively target
the site of tumor via the ASGP receptor-mediated
recognition and significantly reduce its size
Polymeric nanoparticles are the promising
candidates to deliver drugs / peptides
Acknowledgements
• Prof. T. M. Aminabhavi, CEPS, Dharwad
• Prof .P. V. Kulkarni, and Dr. Celeaste,
SWMC, Dallas
• Prof. Sung and Dr. Fafa, National Tsing
Hua University, Taiwan
Thank U

More Related Content

Similar to copolymer

Nanoparticles targetted drug delivery system
Nanoparticles targetted drug delivery systemNanoparticles targetted drug delivery system
Nanoparticles targetted drug delivery systemshashankc10
 
Aptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesAptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesSagugowda
 
Nanotherapy for Cancer
Nanotherapy for CancerNanotherapy for Cancer
Nanotherapy for CancerFawad Majeed
 
harshinanoparticles-180509131830.pdf
harshinanoparticles-180509131830.pdfharshinanoparticles-180509131830.pdf
harshinanoparticles-180509131830.pdfStanlyJohnson7
 
Pharmacokinetic, pharmacodynamic and biodistribution following oral
Pharmacokinetic, pharmacodynamic and biodistribution following oralPharmacokinetic, pharmacodynamic and biodistribution following oral
Pharmacokinetic, pharmacodynamic and biodistribution following oralOsaid Al Meanazel
 
Pharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptxPharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptxDr.Arun Marshalin
 
Targeted drug delivery
Targeted drug deliveryTargeted drug delivery
Targeted drug deliveryNirupama K v
 
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEM
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEMMUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEM
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEMNilanjan Bhattacharya
 
Drug transport across cell membrane.
Drug transport across cell membrane.Drug transport across cell membrane.
Drug transport across cell membrane.Dr. Salman H. Rizvi
 
Tumor targeting drug delivery system
Tumor targeting drug delivery systemTumor targeting drug delivery system
Tumor targeting drug delivery systemSUJITHA MARY
 
Nano-particles and targeting strategies in drug delivery
Nano-particles and targeting strategies in drug deliveryNano-particles and targeting strategies in drug delivery
Nano-particles and targeting strategies in drug deliveryGautham Reddy
 
Nanotechnology based drug delivery
Nanotechnology based drug deliveryNanotechnology based drug delivery
Nanotechnology based drug deliveryAbeer Abd Elrahman
 
Protein And Peptide Drug Delivery System
Protein And Peptide Drug Delivery SystemProtein And Peptide Drug Delivery System
Protein And Peptide Drug Delivery SystemKushal Saha
 
The Novel Drug Delivery System.pptx
The Novel Drug Delivery System.pptxThe Novel Drug Delivery System.pptx
The Novel Drug Delivery System.pptxAbhishek Borkar15
 
Intranasal route of drug administration
Intranasal route of drug administrationIntranasal route of drug administration
Intranasal route of drug administrationDrSahilKumar
 
Protein and peptide delivery
Protein and peptide deliveryProtein and peptide delivery
Protein and peptide deliveryShruti Tyagi
 

Similar to copolymer (20)

6farmaco kin
6farmaco kin6farmaco kin
6farmaco kin
 
Nanoparticles targetted drug delivery system
Nanoparticles targetted drug delivery systemNanoparticles targetted drug delivery system
Nanoparticles targetted drug delivery system
 
Aptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotidesAptamers and antisense oligonucleotides
Aptamers and antisense oligonucleotides
 
Nanotherapy for Cancer
Nanotherapy for CancerNanotherapy for Cancer
Nanotherapy for Cancer
 
nanoparticles
 nanoparticles nanoparticles
nanoparticles
 
harshinanoparticles-180509131830.pdf
harshinanoparticles-180509131830.pdfharshinanoparticles-180509131830.pdf
harshinanoparticles-180509131830.pdf
 
Pharmacokinetic, pharmacodynamic and biodistribution following oral
Pharmacokinetic, pharmacodynamic and biodistribution following oralPharmacokinetic, pharmacodynamic and biodistribution following oral
Pharmacokinetic, pharmacodynamic and biodistribution following oral
 
Pharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptxPharmacokinetics - part I.pptx
Pharmacokinetics - part I.pptx
 
Targeted drug delivery
Targeted drug deliveryTargeted drug delivery
Targeted drug delivery
 
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEM
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEMMUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEM
MUCOADHESIVE IN SITU GELS: A NOVEL NASAL DRUG DELIVERY SYSTEM
 
Drug transport across cell membrane.
Drug transport across cell membrane.Drug transport across cell membrane.
Drug transport across cell membrane.
 
Tumor targeting drug delivery system
Tumor targeting drug delivery systemTumor targeting drug delivery system
Tumor targeting drug delivery system
 
ORGANS-ON-CHIPS
ORGANS-ON-CHIPSORGANS-ON-CHIPS
ORGANS-ON-CHIPS
 
Nano-particles and targeting strategies in drug delivery
Nano-particles and targeting strategies in drug deliveryNano-particles and targeting strategies in drug delivery
Nano-particles and targeting strategies in drug delivery
 
Nano particles and released erythrocytes
Nano particles and released erythrocytesNano particles and released erythrocytes
Nano particles and released erythrocytes
 
Nanotechnology based drug delivery
Nanotechnology based drug deliveryNanotechnology based drug delivery
Nanotechnology based drug delivery
 
Protein And Peptide Drug Delivery System
Protein And Peptide Drug Delivery SystemProtein And Peptide Drug Delivery System
Protein And Peptide Drug Delivery System
 
The Novel Drug Delivery System.pptx
The Novel Drug Delivery System.pptxThe Novel Drug Delivery System.pptx
The Novel Drug Delivery System.pptx
 
Intranasal route of drug administration
Intranasal route of drug administrationIntranasal route of drug administration
Intranasal route of drug administration
 
Protein and peptide delivery
Protein and peptide deliveryProtein and peptide delivery
Protein and peptide delivery
 

More from IBNSINA National Medical College (7)

Prof. M. VIMALA DEVI.ppt
Prof. M. VIMALA DEVI.pptProf. M. VIMALA DEVI.ppt
Prof. M. VIMALA DEVI.ppt
 
Gas Chromatography.pptx
Gas Chromatography.pptxGas Chromatography.pptx
Gas Chromatography.pptx
 
OXIDATIVE REACTION.pptx
OXIDATIVE REACTION.pptxOXIDATIVE REACTION.pptx
OXIDATIVE REACTION.pptx
 
Antipyretic-Analgesic-Nonsteroidal-Antiinflammatory-Drugs.03.Mar.2011.ppt
Antipyretic-Analgesic-Nonsteroidal-Antiinflammatory-Drugs.03.Mar.2011.pptAntipyretic-Analgesic-Nonsteroidal-Antiinflammatory-Drugs.03.Mar.2011.ppt
Antipyretic-Analgesic-Nonsteroidal-Antiinflammatory-Drugs.03.Mar.2011.ppt
 
Chapter08 - 10 Bioavailability & Bioequivalance.ppt
Chapter08 -   10           Bioavailability & Bioequivalance.pptChapter08 -   10           Bioavailability & Bioequivalance.ppt
Chapter08 - 10 Bioavailability & Bioequivalance.ppt
 
5 Recombinant DNA Technology.ppt
5  Recombinant DNA Technology.ppt5  Recombinant DNA Technology.ppt
5 Recombinant DNA Technology.ppt
 
Pharmacokinetic Models
Pharmacokinetic ModelsPharmacokinetic Models
Pharmacokinetic Models
 

Recently uploaded

BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxOH TEIK BIN
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxRaymartEstabillo3
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting DataJhengPantaleon
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Celine George
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxsocialsciencegdgrohi
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityGeoBlogs
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Celine George
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 

Recently uploaded (20)

BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Solving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptxSolving Puzzles Benefits Everyone (English).pptx
Solving Puzzles Benefits Everyone (English).pptx
 
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptxEPANDING THE CONTENT OF AN OUTLINE using notes.pptx
EPANDING THE CONTENT OF AN OUTLINE using notes.pptx
 
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data_Math 4-Q4 Week 5.pptx Steps in Collecting Data
_Math 4-Q4 Week 5.pptx Steps in Collecting Data
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
Incoming and Outgoing Shipments in 1 STEP Using Odoo 17
 
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptxHistory Class XII Ch. 3 Kinship, Caste and Class (1).pptx
History Class XII Ch. 3 Kinship, Caste and Class (1).pptx
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
9953330565 Low Rate Call Girls In Rohini Delhi NCR
9953330565 Low Rate Call Girls In Rohini  Delhi NCR9953330565 Low Rate Call Girls In Rohini  Delhi NCR
9953330565 Low Rate Call Girls In Rohini Delhi NCR
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 

copolymer

  • 1. “POLYMERIC NANOPARTICLES FOR TARGETED DELIVERY” By: Dr. A. R. Kulkarni, Assoc. Professor, Dept of Pharmacology, K.L.E.S’s College of Pharmacy, Belgaum-10
  • 2. “POLYMERIC NANOPARTICLES FOR TARGETED DELIVERY” By: Dr. A. R. Kulkarni, Assoc. Professor, Dept of Pharmacology, K.L.E.S’s College of Pharmacy, Belgaum-10
  • 3. Contents • Introduction to targeted drug delivery system • Bioavailability, efficiency, efficacy • Volume of distribution v/s drug toxicity • Drug receptor concept • Nature of receptors • Site specificity • Antigen- Antibody mechanism • Advantages of targeting • Mechanism of targeting • Classifications of targeting • Importance of transport system • Polymeric nanoparticles
  • 4.
  • 5. Introduction to Targeted Drug Delivery System Definition: ‘Targeted drug delivery’ Carriers, They are drug vectors, Bioavailability F = Bioavailable dose Administered dose Bioavailability – Absolute v/s Relative
  • 6. Drug efficiency: Drug efficacy: Apparent volume of distribution (V) : V = dose administered i.v. plasma concentration Drug toxicity:
  • 7. Ideal systemic delivery vector • Non-toxic vehicle • Non-immunogenic • Condensation of DNA • Intracellular delivery • Targeting ligand • Stabilization of particles
  • 8. Carrier systems used for targeted drug delivery: 1. Colloidal carriers a) Vesicular systems Liposomes, niosomes, pharmacospheres, virosomes. b) Microparticulate system Microparticles, nanoparticles, magnetic microspheres 2. Cellular carriers Released erythrocytes, serum albumin, antibodies, platelets 3. Supramolecular delivery systems Micelles, reverse micelles, mixed micelles, polymeric micelles 4. Polymer based systems Signal sensitive, mucoadhesive, biodegradable, bioerodable 5. Macromolecular carriers a) Proteins b) Glycosylated water soluble polymers c) Toxins, immunotoxin and rCD4 toxin conjugates d) Lectins and polysaccharides
  • 9. Volume of Distribution v/s Drug Toxicity
  • 10. Drug receptor concept • Binding of drugs to receptors necessarily obeys the Law of Mass Action • At equilibrium, receptor occupancy is related to drug concentration by the Hill- Langmuir equation • The higher the affinity of the drug for the receptor, the lower the concentration at which it produces a given level of occupancy
  • 11. • The same principles apply when two or more drugs compete for the same receptors, each has the effect of reducing the apparent affinity of the other
  • 12. Site specificity • Drug is a chemical that affects physiological function in a specific way • With few exceptions drugs act on target proteins namely- enzymes, carriers, ion channels, receptors • Specificity is reciprocal: individual classes of drug bind only to certain targets, & individual targets recognize only certain classes of drug
  • 13. • No drugs are completely specific in their action • In many cases, increasing the dose of a drug will cause it to affect targets other than the principal one, and this can lead to side-effects
  • 15. Mechanism of targeting • Passive targeting • Active targeting • Inverse targeting • Physical targeting • Dual targeting
  • 16. Active targeting further classified into… 1. First order targeting Refers to restricted distribution of the drug carrier system to the cappilary bed of a predetermined target site, organ or tissue Ex. Compartmental targeting in lymphatics, peritoneal cavity, plural cavity, lungs, joints 2. Second order targeting Refers to selective delivery of drugs to a specific cell type such as tumor cells & not the normal cells Ex. The selective drug delivery to the Kupffer cells in the liver exemplifies this approach
  • 17. 3. Third order targeting Refers to drug delivery specifically to the internal (intracellular) site of target cells
  • 18. Physical targeting • This is selective drug delivery programmed & monitored at the external level (ex-vivo) with the help of physical means • In this mode of targeting , some characteristics of the environment are used to direct the carrier to a particular location or to cause selective release of its contents
  • 20. Factors affecting the biodistribution of nanoparticles • Surface hydrophobicity: The higher the nanoparticle hydrophobicity, the faster the nanoparticles are removed from the circulation and taken up by the cells of the MPS • Surface charge: Negative surface charge increases the clearance of nanoparticulates, relative to neutral or positively charged surfaces
  • 21. • Surface size: Nanoparticles more than 5000 nm are normally entrapped in the capillary network of the lungs Nanoparticles less than 100 nm may be able to leave the circulation through gaps or fenestrations in the endothelial cells lining the blood vessels
  • 22. Polymeric nanoparticles • As the name suggests polymeric nanoparticles are nanoparticles which are prepared from polymers • In recent years these have attracted considerable attention as potential drug delivery devices in view of their applications in - drug targeting to particular organ/tissue - as carriers of DNA in gene therapy - ability to deliver proteins, peptides and genes through per oral route of administration
  • 23. • In spite of various synthetic & semisynthetic polymers, natural polymers still enjoy their popularity - gums (ex. Acacia, guar, etc.) - chitosan - gelatin - sodium alginate - albumin • Polymer used must be chemically inert, non- toxic and free of leachable impurities • It must have appropriate physical structure, with minimal undesired aging & be readily processable
  • 24. • Polymers dsigned for medical applications are designed to degrade within the body - polyactides (PLA) - polyglycolides (PGA) - poly (lactide-co-glycolides) (PLGA) - polyanhydrides - polyorthoesters - polycyanoacrylats - polycaprolactone • Advantage of degradable polymers- they are broken down into biologically acceptable molecules that are metabolized and removed from the body via normal metabolic pathways
  • 25. Fact: • Abraxane is first polymeric nanoparticle based product from American Pharmaceutical Partners, Inc., and American Bioscience, Inc. (ABI) • It was approved in the year 2005 and is consisting of albumin bound paclitaxel nanoparticles
  • 26. Emulsion polymerization • In this method, the monomer is dispersed in aqueous solution as a uniform emulsion and stabilized by the surfactants. • Dispersion of the surfactant persists until the critical micellar concentration (CMC) is realized. • The anionic polymerization of polyalklycyanoacrylate monomers into polymeric NPs follows the emulsion polymerization technique. PRODUCTION OF NANOPARTICLES BY DIFFERENT TECHNIQUES
  • 27. • Dispersion polymerization NPs of polyacrylamide (PAM) by the dispersion polymerization of acrylamide monomer at 40°C. They used the partial isopropyl ester derivative of poly(vinyl methyl ether-alt-maleicanhydride) (PVME-alt-MA), called PVME-co-MA-co-iPrMA, as the stabilizer, and ammonium persulfate (APS) as the initiator. • Solvent diffusion and evaporation Water insoluble polymers can be used for production of NPs.
  • 28. • The in vivo biodistribution of NPs is greatly influenced by their interactions with the plasma proteins. • Opsonization by plasma proteins renders the NPs more vulnerable to mononuclear phagocytotic attack, mainly by the Kupffer cells of the liver. • In fact, the main disadvantage of drug targeting to the CNS is the rapid uptake of NPs by the macrophages of the RES, thus hindering NP applications in controlled drug delivery and drug targeting, to tissues other than those of the RES. SURFACE MODIFICATION OF NANOPARTICLES
  • 29. • Therapeutic drug levels of the targeted (e.g., brain) drug-loaded NPs are therefore difficult to reach. Tween-80 • It was demonstrated that substances which could not otherwise cross the BBB, can induce permeability when the substance is bound onto the surfaces of poly (cyanoacrylate) nanoparticles, and coated with surfactants, such as Tween-80. • It seemed that brain targeting of nanoparticles was concerned with the interaction between Tween-80 coating and brain micro-vessel endothelial cells.
  • 30. • Kreuter et al have extensively discussed the nanoparticle mediated drug transport to the brain overcoated with polysorbates and other surfactants. Polyethylene glycol • The presence of the hydrophilic coating on the surface of the nanoparticles is thought to sterically stabilize them against opsonization and phagocytocis. • Among the hydrophilic polymers, polyethylene glycol (PEG) has been found to be a particularly effective steric stabilizer, probably due to its high hydrophilicity, chain flexibility, electrical neutrality and absence of functional groups, which prevent interactions with the biological components in vivo.
  • 31. • The NP surface coating with hydrophilic polymers such as PEG has been shown to confer long circulation properties to poly(lactide) (PLA), poly(lactide-co- glycolide) (PLGA), poly (caprolactone) (PCL) and poly (phosphazene) and poly(cyanoacrylate) nanoparticles. Poloxamer/Poloxamine • The drug-loaded NPs were surface-modified with block copolymers of the poloxamer 407 or poloxamine 908 series, and administered intravenously to rats under study. • It was demonstrated that the blood circulation half-life was increased by its encapsulation in the surface- modified NPs (25-30 min), whereas uncoated NPs rapidly cleared from the blood (only 8 % remaining after 5 min).
  • 32. • Additionally, the amount of NPs in the liver was found to significantly decrease after NPs encapsulation within the modified NPs. • Similar correlations were made regarding decreases in splenic uptake of coated nanoparticles. Thus, PLGA nanoparticles successfully escaped capture by the RES.
  • 33.
  • 35. Effects of the CS-γ-PGA NPs on the TEER values of Caco-2 cells. + Chitosan + + + + + + + + + γPGA Nanoparticles with a positive surface charge were able to reduce the values of TEER. Time (hr) TEER of Initial Value (%) 1 2 3 0 4 20 40 60 80 100 120 Control Group 0.01% -PGA:0.05% CS 0.10% -PGA:0.20% CS 0.20% -PGA:0.01% CS (n = 3) Removal of Nanoparticles Time (hr) TEER of Initial Value (%) 0 4 8 12 16 20 24 20 40 60 80 100 120 Removal of Nanoparticles Control Group 0.01% -PGA:0.05% CS 0.10% -PGA:0.20% CS 0.20% -PGA:0.01% CS (n = 3) Figure 2. Effects of the prepared CS–- PGA nanoparticles on the TEER values of Caco-2 cell monolayers.
  • 36.
  • 38. we have developed paclitaxel-loaded formulations using the nanoparticles for the treatment of cancers. Paclitaxel is one of the most active anticancer drugs introduced in cancer chemotherapy Even though paclitaxel is prescribed mainly to treat breast and ovarian cancers, it is known that various cancer cells including hepatoma cells can be killed effectively by this drug PACLITAXEL- LOADED NANOPARTICLES
  • 39. Nanoparticles may be delivered to specific sites by size-dependant passive targeting or by active targeting Hepatoma cells are known to recognize galactose- and N-acetylgalactosamine-terminated glycoproteins via the asialoglycoprotein (ASGP) receptors located on their surfaces Galactosylated Nanoparticle Galactosamine
  • 40. Synthesis of γ-PGA-PLA block copolymers PGA produced by Bacillus licheniformis (ATCC 9945, Bioresources Collection and Research Center, Hsinchu, Taiwan) and purified Block copolymers composed of PGA and PLA were synthesized using CDI to activate the terminal hydroxyl group of PLA Galactosamine was conjugated to the paclitaxel-loaded nanoparticles via an amide linkage by EDC
  • 41. OH C O CH CH3 n PLA O CH2 O O C O CH CH3 n O CH2 O C N O N -PGA m NH CH CH2 CH2 C C O OH O NH2 OH Amphiphilic Block Copolymer N N C N O N Galactosylated Nanoparticle Galactosamine CDI Activated PLA
  • 43.
  • 44. Particle size, zeta potential, and drug loading content (LC) and loading efficiency (LE) of the paclitaxel-loaded nanoparticles without (NPs) or with (Gal-NPs) galactosamine Samples (n = 4) Particle Size (nm) Zeta Potential (mV) LC (%) LE (%) NPs 128.8 ± 3.4 -19.6 ± 1.8 5.1 ± 0.2 53..7 ± 1.6 Gal-NPs 127.5 ± 2.5 -10.6 ± 2.0 4.8 ± 0.2 50..2 ± 2.1
  • 45. -20 0 20 40 60 80 100 120 140 160 10 20 30 40 50 60 70 80 90 100 Accumulative Release of Paclitaxel (%) Time (h) NPs Gal-NPs (n = 4) -1 0 1 2 3 4 5 6 7 8 9 60 65 70 75 80 85 90 95 100 105 Phyxol NPs Gal-NPs (n = 4)
  • 46. Incubation for 1 day Cells were fixed with 3.7% formaldehyde in PBS cells were stained with Oregon Green and propidium iodide (PI, Sigma) that specifically bind to F-actin and the nucleus, respectively. Additionally, microtubule networks were revealed using a monoclonal anti-bovine -tubulin, with an anti-mouse IgG-Alexa Fluor 633 (Molecular Probes). Immunofluorescence analysis
  • 47. F-actin Nucleus Microtubule Merge N N n Control Phyxol  n Immunofluorescence analysis
  • 48. Liver Spleen Tumor NPs Gal-NPs NPs or the Gal-NPs loaded with rhodamine 123
  • 50. 1 2 3 4 5 6 0 10 20 30 40 50 60 70 80 90 100 110 120 130 Tumor Kidney Lung Liver Spleen Brain Blood Intensity (counts/mg tissue) 1 h after injection 8 h after injection 24 h after injection (n=4) 1 2 3 4 5 0 10 20 30 40 50 60 70 80 90 100 110 120 Tumor Kidney Lung Liver Spleen Brain Blood Intensity (counts/mg tissue) 1 hafterinjection 8 hafterinjection 24 hafterinjection (n=4)
  • 51. 0 2 4 6 8 10 12 14 16 18 20 22 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 Changes in the Body Weight ( %) PBS Phyxol NPs Gal-NPs
  • 52. CONCLUSIONS Drug-loaded nanoparticles with galactosamine conjugated prepared in the study can effectively target the site of tumor via the ASGP receptor-mediated recognition and significantly reduce its size Polymeric nanoparticles are the promising candidates to deliver drugs / peptides
  • 53.
  • 54.
  • 55. Acknowledgements • Prof. T. M. Aminabhavi, CEPS, Dharwad • Prof .P. V. Kulkarni, and Dr. Celeaste, SWMC, Dallas • Prof. Sung and Dr. Fafa, National Tsing Hua University, Taiwan